KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EPS (Basic) (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed EPS (Basic) for 8 consecutive years, with $0.32 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 390.91% year-over-year to $0.32, compared with a TTM value of -$0.11 through Dec 2025, up 52.17%, and an annual FY2025 reading of -$0.11, up 60.71% over the prior year.
  • EPS (Basic) was $0.32 for Q4 2025 at Esperion Therapeutics, up from -$0.16 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.36 in Q1 2024 and bottomed at -$3.5 in Q1 2021.
  • Average EPS (Basic) over 5 years is -$0.76, with a median of -$0.48 recorded in 2023.
  • Peak annual rise in EPS (Basic) hit 390.91% in 2025, while the deepest fall reached 158.33% in 2025.
  • Year by year, EPS (Basic) stood at -$1.53 in 2021, then skyrocketed by 51.63% to -$0.74 in 2022, then soared by 32.43% to -$0.5 in 2023, then surged by 78.0% to -$0.11 in 2024, then skyrocketed by 390.91% to $0.32 in 2025.
  • Business Quant data shows EPS (Basic) for ESPR at $0.32 in Q4 2025, -$0.16 in Q3 2025, and -$0.06 in Q2 2025.